Table 1.
Correlation between different expression levels of cx3cl1 and CCL28 and clinical data.
| Characteristics | CX3CL1 | P | CCL28 | P | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| -/+ (%) | ++ (%) | +++ (%) | -/+(%) | ++(%) | +++(%) | |||||
| Gender | Female | 21 | 4 (19.0) | 14 (66.7) | 3 (14.3) | 0.592 | 3 (14.3) | 15 (71.4) | 3 (14.3) | 0.549 |
| Male | 19 | 4 (21.1) | 11 (57.9) | 4 (21.1) | 2 (10.5) | 12 (63.2) | 5 (26.3) | |||
| Age (years) | ≥60 | 30 | 6 (20.0) | 19 (63.3) | 5 (16.7) | 0.688 | 4 (13.3) | 21 (70.0) | 5 (16.7) | 0.633 |
| <60 | 10 | 2 (20.0) | 6 (60.0) | 2 (20.0) | 1 (10.0) | 6 (60.0) | 3 (30.0) | |||
| Number of bonemetastases | Single | 8 | 3 (37.5) | 3 (37.5) | 2 (25.0) | 0.320 | 4 (50.0) | 2 (25.0) | 2 (25.0) | 0.507 |
| Multiple | 32 | 5 (15.6) | 22 (68.75) | 5 (15.6) | 1 (3.1) | 25 (78.1) | 6 (18.8) | |||
| ECOG scores∗ | 0–2 | 12 | 6 (50.0) | 4 (33.3) | 2 (16.6) | 0.005 | 4 (33.3) | 6 (50.0) | 2 (16.7) | 0.022 |
| 3–4 | 28 | 2 (7.1) | 21 (75) | 5 (17.9) | 1 (3.6) | 21 (75.0) | 6 (21.4) | |||
| Chemotherapy | No | 17 | 2 (11.8) | 10 (58.9) | 5 (29.4) | 0.428 | 2 (11.8) | 13 (76.5) | 2 (11.8) | 0.646 |
| Yes | 23 | 6 (26.1) | 15 (65.2) | 2 (8.7) | 3 (13.0) | 14 (60.9) | 6 (26.1) | |||
| Visceral metastasis∗ | No | 8 | 5 (62.5) | 2 (25.0) | 1 (12.5) | 0.004 | 4 (50.0) | 2 (25.0) | 2 (25.0) | 0.003 |
| Yes | 32 | 3 (9.4) | 23 (71.9) | 6 (18.8) | 1 (3.1) | 25 (78.1) | 6 (18.8) | |||
∗ P＜0.05, indicating statistical significance.